🚀 VC round data is live in beta, check it out!
Eton Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Eton Pharmaceuticals and similar public comparables like Bioage Labs, Zentiva, Astria Therapeutics, Alto Neuroscience and more.
Eton Pharmaceuticals Overview
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Founded
2017
HQ
Employees
30
Website
Sectors
Financials (LTM)
EV
$724M
Eton Pharmaceuticals Financials
Eton Pharmaceuticals reported last 12-month revenue of $88M and EBITDA of $21M.
In the same LTM period, Eton Pharmaceuticals generated $52M in gross profit, $21M in EBITDA, and $2M in net income.
Revenue (LTM)
Eton Pharmaceuticals P&L
In the most recent fiscal year, Eton Pharmaceuticals reported revenue of $80M and EBITDA of $16M.
Eton Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $88M | XXX | $80M | XXX | XXX | XXX |
| Gross Profit | $52M | XXX | $43M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $21M | XXX | $16M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $2M | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | 3% | XXX | (6%) | XXX | XXX | XXX |
| Net Debt | — | — | $5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Eton Pharmaceuticals Stock Performance
Eton Pharmaceuticals has current market cap of $719M, and enterprise value of $724M.
Market Cap Evolution
Eton Pharmaceuticals' stock price is $26.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $724M | $719M | -2.7% | XXX | XXX | XXX | $-0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEton Pharmaceuticals Valuation Multiples
Eton Pharmaceuticals trades at 8.2x EV/Revenue multiple, and 35.2x EV/EBITDA.
EV / Revenue (LTM)
Eton Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, Eton Pharmaceuticals has market cap of $719M and EV of $724M.
Equity research analysts estimate Eton Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eton Pharmaceuticals has a P/E ratio of 293.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $719M | XXX | $719M | XXX | XXX | XXX |
| EV (current) | $724M | XXX | $724M | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBITDA | 35.2x | XXX | 45.8x | XXX | XXX | XXX |
| EV/EBIT | 68.2x | XXX | 167.0x | XXX | XXX | XXX |
| EV/Gross Profit | 13.9x | XXX | 16.9x | XXX | XXX | XXX |
| P/E | 293.3x | XXX | (156.3x) | XXX | XXX | XXX |
| EV/FCF | 52.5x | XXX | 71.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eton Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eton Pharmaceuticals Margins & Growth Rates
Eton Pharmaceuticals' revenue in the last 12 month grew by 41%.
Eton Pharmaceuticals' revenue per employee in the last FY averaged $2.7M, while opex per employee averaged $1.5M for the same period.
Eton Pharmaceuticals' rule of 40 is 68% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eton Pharmaceuticals' rule of X is 125% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Eton Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 98% | XXX | 109% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 68% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 125% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 42% | XXX | 45% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Eton Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioage Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Astria Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alto Neuroscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexicon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eton Pharmaceuticals M&A Activity
Eton Pharmaceuticals acquired XXX companies to date.
Last acquisition by Eton Pharmaceuticals was on XXXXXXXX, XXXXX. Eton Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Eton Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEton Pharmaceuticals Investment Activity
Eton Pharmaceuticals invested in XXX companies to date.
Eton Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Eton Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Eton Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eton Pharmaceuticals
| When was Eton Pharmaceuticals founded? | Eton Pharmaceuticals was founded in 2017. |
| Where is Eton Pharmaceuticals headquartered? | Eton Pharmaceuticals is headquartered in United States. |
| How many employees does Eton Pharmaceuticals have? | As of today, Eton Pharmaceuticals has over 30 employees. |
| Who is the CEO of Eton Pharmaceuticals? | Eton Pharmaceuticals' CEO is Sean E. Brynjelsen. |
| Is Eton Pharmaceuticals publicly listed? | Yes, Eton Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Eton Pharmaceuticals? | Eton Pharmaceuticals trades under ETON ticker. |
| When did Eton Pharmaceuticals go public? | Eton Pharmaceuticals went public in 2018. |
| Who are competitors of Eton Pharmaceuticals? | Eton Pharmaceuticals main competitors are Bioage Labs, Zentiva, Astria Therapeutics, Alto Neuroscience. |
| What is the current market cap of Eton Pharmaceuticals? | Eton Pharmaceuticals' current market cap is $719M. |
| What is the current revenue of Eton Pharmaceuticals? | Eton Pharmaceuticals' last 12 months revenue is $88M. |
| What is the current revenue growth of Eton Pharmaceuticals? | Eton Pharmaceuticals revenue growth (NTM/LTM) is 41%. |
| What is the current EV/Revenue multiple of Eton Pharmaceuticals? | Current revenue multiple of Eton Pharmaceuticals is 8.2x. |
| Is Eton Pharmaceuticals profitable? | Yes, Eton Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eton Pharmaceuticals? | Eton Pharmaceuticals' last 12 months EBITDA is $21M. |
| What is Eton Pharmaceuticals' EBITDA margin? | Eton Pharmaceuticals' last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Eton Pharmaceuticals? | Current EBITDA multiple of Eton Pharmaceuticals is 35.2x. |
| What is the current FCF of Eton Pharmaceuticals? | Eton Pharmaceuticals' last 12 months FCF is $14M. |
| What is Eton Pharmaceuticals' FCF margin? | Eton Pharmaceuticals' last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Eton Pharmaceuticals? | Current FCF multiple of Eton Pharmaceuticals is 52.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.